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Background
The gp41 cluster I is a conserved immunodominant
loop connecting the heptad repeat 1 (HR 1) and heptad
repeat 2 (HR2) of the HIV-1 the envelope glycoproteins
(Env). Following HIV-1 infection or vaccination with
gp41-containing Env immunogens, this region elicits
relatively high titers of antibodies generally considered
to be non-neutralizing in nature. However, in a recent
passive immunization study using a cluster 1 antibody,
partial protection against SHIV SF162 P4 challenge was
observed. In the present study, we sought to determine
if vaccine-elicited cluster 1 antibodies might afford some
protective capacity by active vaccination, presumably by
binding to non-functional spikes on the virus and slow-
ing the viral entry process in vivo.
Methods
To generate cluster 1-specific antibodies, we added resi-
dues flanking the cluster I cysteine-loop region to allow it
to assume its preferred structural conformation. The
resultant 20 residues peptides were expressed on the
genetically modified Q-beta bacteriophage particles and
also chemically coupled to KLH. Sera from rabbits immu-
nized with these antigens were analyzed by ELISA for the
binding to cluster 1 peptides and by cross-competition
with the known cluster I antibodies.
Results
The cluster I region was found to be immunogenic and,
interestingly, a version of the epitope in which alanines
were substituted in place of the small cysteine-linked loop
was found to be more immunogenic than the wild-type
cysteine-cysteine motif. The sera from rabbits inoculated
with either carrier cross-competed with the known cluster
I antibodies such as F240. Though the sera did not
neutralize JR-FL viruses, they serum antibodies were able
to capture many different viruses in vitro.
Conclusion
We conclude that we have specifically elicited antibodies
directed to the cluster 1 region of gp41 possessing proper-
ties similar to the known monoclonal antibodies. Active
immunization of non-human primates by both the intra-
nasal and intramuscular routes, followed by SHIV.
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